My Locations
About Me
I care for children with childhood arthritis, autoimmune, and autoinflammatory conditions. The relationship I build with my patients and families is one of the most rewarding parts of my career. I believe it is that collaborative relationship that is crucial to managing these often chronic conditions that affect children so differently. I also remain committed to providing opportunities for patients and families to become involved in research and advocacy to help to move the field forward and improve the care we offer to children. With our joint commitment, we will be able to advance our knowledge, optimize available treatments, and eventually find a cure for these rare conditions.

- Professor of Pediatrics, Pediatrics, Rheumatology 2021
- Vice Dean for Faculty, School of Medicine 2022
- Member in the Duke Clinical Research Institute, Duke Clinical Research Institute 2019
Call for an Appointment
Training and Education
Clinical Focus and Research
My research interest is to enhance response and minimize the toxicity of drugs used for the treatment of rheumatic diseases in children, focusing on an individualized therapeutic strategy. I want to find the right medication, for the right child, at the right time, and I am also committed to getting safe and effective medications on the market for children. My current translational research focuses on the commonly used drug, methotrexate, and its effect upon the body's folate pathway. Throughout the years, my work has been funded by the Kansas City Areas Life Sciences Institute, the PhRMA Foundation, the Rheumatology Research Foundation, and the National Institutes of Health.
- Becker, M. L. Skin Target Lesion, 2011. https://doi.org/10.1002/9781444397994.ch76.
- Becker, M. L. Rash and Joint Pain in a Child, 2011. https://doi.org/10.1002/9781444397994.ch40.
- Soulsby, William Daniel, Rebecca Olveda, Jie He, Laura Berbert, Edie Weller, Kamil E. Barbour, Kurt J. Greenlund, et al. “Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study.” Arthritis Care Res (Hoboken) 77, no. 1 (January 2025): 38–49. https://doi.org/10.1002/acr.25443.
- Rael, Victoria E., Julian A. Yano, John P. Huizar, Leianna C. Slayden, Madeleine A. Weiss, Elizabeth A. Turcotte, Jacob M. Terry, et al. “Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans.” J Exp Med 221, no. 8 (August 5, 2024). https://doi.org/10.1084/jem.20232005.
- Mannion, Melissa L., Shahla Amin, Stephen Balevic, Min-Lee Chang, Colleen K. Correll, Lianne Kearsley-Fleet, Kimme L. Hyrich, Timothy Beukelman, and Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators. “Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.” Arthritis Care Res (Hoboken) 76, no. 8 (August 2024): 1090–98. https://doi.org/10.1002/acr.25339.
- Becker, M. L., D. Lovell, and S. J. Leeder. “Pharmacology and Drug Therapy: Nonbiologic Therapies.” In Textbook of Pediatric Rheumatology, 140–60, 2015. https://doi.org/10.1016/B978-0-323-24145-8.00012-0.
- Kumar, A., J. Tatarian, V. Shakhnovich, R. L. Chevalier, M. Sudman, D. J. Lovell, S. D. Thompson, M. L. Becker, and R. S. Funk. “Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis.” In Metabolites, Vol. 14, 2024. https://doi.org/10.3390/metabo14090499.
- Jones, Jordan T., Chelsey Smith, Mara L. Becker, Daniel Lovell, and CARRA Registry Investigators. “Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes.” In Arthritis Care Res (Hoboken), 73:1739–45, 2021. https://doi.org/10.1002/acr.24418.
- Li, Suzanne, Aaron Thammavongxay, Maria Ibarra, Kathryn Torok, Polly Ferguson, C Egla Rabinovich, Robert Fuhlbrigge, et al. “Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans).” In ARTHRITIS & RHEUMATOLOGY, 73:1598–1601, 2021.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- American College of Rheumatology
- Canadian Arthritis Society
- Childhood Arthritis and Rheumatology Research Alliance
- Doris Duke Charitable Foundation
- Food and Drug Administration
- PCORI
- The Duke Endowment